JP2009523847A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523847A5
JP2009523847A5 JP2008552360A JP2008552360A JP2009523847A5 JP 2009523847 A5 JP2009523847 A5 JP 2009523847A5 JP 2008552360 A JP2008552360 A JP 2008552360A JP 2008552360 A JP2008552360 A JP 2008552360A JP 2009523847 A5 JP2009523847 A5 JP 2009523847A5
Authority
JP
Japan
Prior art keywords
cells
subject
cell
administered
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008552360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523847A (ja
JP5986346B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/001747 external-priority patent/WO2007087293A2/en
Publication of JP2009523847A publication Critical patent/JP2009523847A/ja
Publication of JP2009523847A5 publication Critical patent/JP2009523847A5/ja
Application granted granted Critical
Publication of JP5986346B2 publication Critical patent/JP5986346B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008552360A 2006-01-23 2007-01-23 補助的免疫抑制処置を行わないｍａｐｃ療法 Expired - Fee Related JP5986346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76095106P 2006-01-23 2006-01-23
US60/760,951 2006-01-23
PCT/US2007/001747 WO2007087293A2 (en) 2006-01-23 2007-01-23 Mapc therapeutics without adjunctive immunosuppressive treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013150338A Division JP6344892B2 (ja) 2006-01-23 2013-07-19 補助的免疫抑制処置を行わないｍａｐｃ療法

Publications (3)

Publication Number Publication Date
JP2009523847A JP2009523847A (ja) 2009-06-25
JP2009523847A5 true JP2009523847A5 (enExample) 2010-03-11
JP5986346B2 JP5986346B2 (ja) 2016-09-06

Family

ID=38123870

Family Applications (11)

Application Number Title Priority Date Filing Date
JP2008552360A Expired - Fee Related JP5986346B2 (ja) 2006-01-23 2007-01-23 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2013150313A Active JP6338331B2 (ja) 2006-01-23 2013-07-19 脳損傷及び疾患のｍａｐｃ治療
JP2013150338A Active JP6344892B2 (ja) 2006-01-23 2013-07-19 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2016201854A Active JP6509795B2 (ja) 2006-01-23 2016-10-13 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2016201847A Active JP6502301B2 (ja) 2006-01-23 2016-10-13 脳損傷及び疾患のｍａｐｃ治療
JP2018237463A Expired - Fee Related JP6871899B2 (ja) 2006-01-23 2018-12-19 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2019006297A Withdrawn JP2019056015A (ja) 2006-01-23 2019-01-17 脳損傷及び疾患のｍａｐｃ治療
JP2020093132A Withdrawn JP2020128427A (ja) 2006-01-23 2020-05-28 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2020209942A Withdrawn JP2021042258A (ja) 2006-01-23 2020-12-18 脳損傷及び疾患のｍａｐｃ治療
JP2022110378A Pending JP2022125317A (ja) 2006-01-23 2022-07-08 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2023137277A Pending JP2023153391A (ja) 2006-01-23 2023-08-25 脳損傷及び疾患のｍａｐｃ治療

Family Applications After (10)

Application Number Title Priority Date Filing Date
JP2013150313A Active JP6338331B2 (ja) 2006-01-23 2013-07-19 脳損傷及び疾患のｍａｐｃ治療
JP2013150338A Active JP6344892B2 (ja) 2006-01-23 2013-07-19 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2016201854A Active JP6509795B2 (ja) 2006-01-23 2016-10-13 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2016201847A Active JP6502301B2 (ja) 2006-01-23 2016-10-13 脳損傷及び疾患のｍａｐｃ治療
JP2018237463A Expired - Fee Related JP6871899B2 (ja) 2006-01-23 2018-12-19 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2019006297A Withdrawn JP2019056015A (ja) 2006-01-23 2019-01-17 脳損傷及び疾患のｍａｐｃ治療
JP2020093132A Withdrawn JP2020128427A (ja) 2006-01-23 2020-05-28 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2020209942A Withdrawn JP2021042258A (ja) 2006-01-23 2020-12-18 脳損傷及び疾患のｍａｐｃ治療
JP2022110378A Pending JP2022125317A (ja) 2006-01-23 2022-07-08 補助的免疫抑制処置を行わないｍａｐｃ療法
JP2023137277A Pending JP2023153391A (ja) 2006-01-23 2023-08-25 脳損傷及び疾患のｍａｐｃ治療

Country Status (11)

Country Link
US (3) US11992507B2 (enExample)
EP (3) EP3345610A1 (enExample)
JP (11) JP5986346B2 (enExample)
CN (5) CN101410125A (enExample)
AU (1) AU2007208368B2 (enExample)
CA (5) CA3124132A1 (enExample)
DK (1) DK1986668T3 (enExample)
HK (2) HK1201481A1 (enExample)
NZ (3) NZ744465A (enExample)
PT (1) PT1981515E (enExample)
WO (1) WO2007087293A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2581752Y2 (ja) 1993-11-11 1998-09-24 株式会社三東工業社 二重薬液案内路を有する伸縮式掘削作業ロッド
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
ZA200200049B (en) 2001-01-25 2002-07-16 Nippon Catalytic Chem Ind Fixed-bed shell-and-tube reactor and its usage.
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
DK2471904T3 (en) 2005-12-29 2019-02-18 Celularity Inc Placenta stem cell populations
US11992507B2 (en) 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
CA2850793A1 (en) 2006-10-23 2008-05-02 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
HRP20130765T1 (hr) 2007-02-12 2013-10-25 Anthrogenesis Corporation Lijeäśenje protuupalnih bolesti putem matiäśnih stanica posteljice
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CA2712496C (en) 2008-01-18 2021-01-12 Wei-Shou Hu Stem cell aggregates and methods for making and using
MX339624B (es) * 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
EP2331109B1 (en) * 2008-08-22 2013-05-29 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
CN107095883A (zh) * 2008-09-04 2017-08-29 Abt控股公司 干细胞预防神经元顶梢枯死的用途
CA2743566C (en) 2008-11-19 2021-11-09 Anthrogenesis Corporation Amnion derived adherent cells
AU2013231210B2 (en) * 2009-07-21 2014-11-20 Healios K.K. Use of stem cells to reduce leukocyte extravasation
SG10201404281YA (en) * 2009-07-21 2014-09-26 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation
AU2013237687B2 (en) * 2009-07-21 2014-11-20 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
RU2424004C1 (ru) * 2009-11-12 2011-07-20 Государственное образовательное учреждение дополнительного профессионального образования Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию Способ лечения перинатального поражения головного мозга гипоксически-ишемического генеза у детей первого года жизни
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
BR112012021451B8 (pt) * 2010-02-25 2021-05-25 Abt Holding Co uso de células que apresentam uma eficiência desejada para a expressão e/ou secreção dos fatores pró-angiogênicos vegf, cxcl5 e il8, métodos para construir um banco de células, para desenvolver fármaco, e para aumentar a expressão de um ou mais fatores pró-angiogênicos em uma célula realizado in vitro, e, composição
TW201703777A (zh) 2010-04-07 2017-02-01 安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
NZ602798A (en) 2010-04-08 2014-10-31 Anthrogenesis Corp Treatment of sarcoidosis using placental stem cells
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
CN104220081A (zh) 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛
WO2014123879A1 (en) 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta
AU2014250761B2 (en) 2013-04-12 2019-02-28 Robert J. Deans Improving organs for transplantation
US20160326494A1 (en) * 2015-05-05 2016-11-10 Katholieke Universiteit Leuven Methods for Pancreatic Islet Transplantation
HK1256413A1 (zh) 2016-01-21 2019-09-20 Abt Holding Company 用於伤口癒合的干细胞
RU2753508C2 (ru) 2017-03-17 2021-08-17 Мицубиси Кемикал Корпорейшн Способ каталитического окисления и способ получения сопряженного диена
US20200246390A1 (en) * 2019-02-01 2020-08-06 Abt Holding Company Multipotent adult projenitor cells for treatment of ich
TWI825446B (zh) * 2020-08-14 2023-12-11 中國醫藥大學 醫藥組合物治療組織缺血狀況之用途
WO2022196233A1 (ja) 2021-03-16 2022-09-22 日本碍子株式会社 ガスセンサ素子及びガスセンサ

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
GB2244058B (en) 1990-05-01 1993-03-24 Courtaulds Films & Packaging Packaging materials
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2169292C (en) * 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
IN184685B (enExample) 1996-02-14 2000-09-23 Nat Inst Immunology
US5839275A (en) 1996-08-20 1998-11-24 Toyota Jidosha Kabushiki Kaisha Fuel injection control device for a direct injection type engine
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
DK1007631T4 (da) 1997-07-14 2009-04-27 Osiris Therapeutics Inc Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU1508899A (en) 1997-12-02 1999-06-16 Chong Kun Dang Corporation Pharmaceutical composition comprising cyclosporin solid-state microemulsion
EP1062321B1 (en) 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2320040C (en) 1998-03-18 2007-05-22 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6797269B2 (en) 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
WO2005113748A2 (en) 2004-04-21 2005-12-01 Regents Of The University Of Minnesota Mapc generation of lung tissue
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
DK1226233T3 (da) * 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20030044843A1 (en) 2001-01-09 2003-03-06 Mitsubishi Pharma Corporation Novel proteome analysis method and devices therefor
CA2438501C (en) 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
JP4628618B2 (ja) 2001-09-26 2011-02-09 富士フイルム株式会社 撮像光学系
AU2003209259A1 (en) * 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
KR100667746B1 (ko) 2002-07-15 2007-01-11 삼성전자주식회사 드라이브 정보가 기록된 정보저장 매체 및 그 기록 방법
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
WO2004069172A2 (en) 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
WO2004099395A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
WO2004099394A2 (en) 2003-05-08 2004-11-18 Cellartis Ab A method for efficient transfer of human blastocyst-derived stem cells (hbs cells) from a feeder-supported to a feeder-free culture system
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
CA2530421C (en) 2003-06-27 2015-04-21 Ethicon, Incorporated Repair and regeneration of ocular tissue using postpartum-derived cells
JP2007513188A (ja) * 2003-12-04 2007-05-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ リソソーム蓄積症の処置のための組成物および方法
AU2005331559B2 (en) 2005-05-05 2012-04-19 Regents Of The University Of Minnesota Use of NK cell inhibition to facilitate persistence of engrafted MHC-I negative cells
US20080311084A1 (en) 2005-05-05 2008-12-18 Verfaillie Catherine M Mapc Engraftment in the Hematopoietic System
TW200726474A (en) * 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
EP2368973A1 (en) 2005-10-13 2011-09-28 Anthrogenesis Corporation Production Of Oligodendrocytes From Placenta-Derived Stem Cells
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US11992507B2 (en) 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
HRP20130765T1 (hr) 2007-02-12 2013-10-25 Anthrogenesis Corporation Lijeäśenje protuupalnih bolesti putem matiäśnih stanica posteljice
US20120121545A1 (en) 2009-01-15 2012-05-17 Corestem Co., Ltd. Pharmaceutical Composition For Bone Disease Treatment Or Countering Inflammation, Comprising Cartilage Stem Cells As An Active Principle
EP2241617A1 (en) 2009-04-06 2010-10-20 Rijksuniversiteit Groningen Multipotent cells derived from blood and methods and uses related thereto

Similar Documents

Publication Publication Date Title
JP2009523847A5 (enExample)
Shyu et al. Homing genes, cell therapy and stroke
ES2778424T3 (es) Propiedades inmunomoduladoras de las células progenitoras adultas multipotentes y usos de las mismas
Karussis et al. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases
Forostyak et al. The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications
Uccelli et al. Mesenchymal stem cells: a new strategy for immunosuppression?
Olson et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington’s disease
Shang et al. NT-3-secreting human umbilical cord mesenchymal stromal cell transplantation for the treatment of acute spinal cord injury in rats
Aras et al. The effects of adipose tissue-derived mesenchymal stem cell transplantation during the acute and subacute phases following spinal cord injury
US10792309B2 (en) Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient
EP2422800A3 (en) Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
Xie et al. Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats
Vandermeulen et al. Rationale for the potential use of mesenchymal stromal cells in liver transplantation
CA2747794A1 (en) Treatment of lung and pulmonary diseases and disorders
Dressel Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells
Gan et al. Hematopoietic recovery of acute radiation syndrome by human superoxide dismutase–expressing umbilical cord mesenchymal stromal cells
Staels et al. Accessory cells for β‐cell transplantation
Haider et al. Angiomyogenesis for myocardial repair
Lonyai et al. The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases
Kuraitis et al. The future of regenerating the myocardium
Mukhamedshina et al. Genetically modified human umbilical cord blood cells as a promising strategy for treatment of spinal cord injury
CN113041262B (zh) 内胚层干细胞在预防和/或治疗肝脏免疫失调疾病中的应用
Nursalim et al. Cellular cardiomyoplasty for myocardial infarction: A 2014 evidence-based update
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
Gunzburg et al. Stem cell therapies: on track but suffer setback